Delivery Order SPE2DB20D3103-SPE2DB22FP8L5

Award Date 9/12/22
Potential Completion Date 9/13/22
Potential Value $3.3K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $2,066.59 firm fixed-price delivery order is for the supply of XIFAXAN 550 mg tablets. The contract has an ultimate completion date of December 2, 2022. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for...
This federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, is for the supply of XIFAXAN 550 mg tablets to the Defense Logistics Agency (DLA). The contract is a Delivery Order with a Firm Fixed Price of $30,902.72 and an ultimate completion date of July 17, 2024. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical...
This is a federal contract award from the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $10,747.00 firm fixed-price delivery order is for the supply of XIFAXAN 550 MG TABLET 60S, a pharmaceutical product. The contract has an ultimate completion date of February 14, 2024. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $33,456.21 delivery order is for the supply of XIFAXAN 550 MG tablets and is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which covers a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $4,687.91 firm fixed-price delivery order is for the supply of XIFAXAN 550 mg tablets. The contract has a completion date of November 15, 2024 and is not designated as a set-aside. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a...
This federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, was issued by the Defense Logistics Agency (DLA) Troop Support Medical. The $26,448.21 firm fixed-price Delivery Order is for the supply of XIFAXAN 550 mg tablets to support federal healthcare programs. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical...
This federal contract award was made by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $5,824.14 firm fixed-price delivery order is for the supply of XIFAXAN 550 MG TABLET 60S, a pharmaceutical product. The award is not associated with a set-aside program. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary...
This federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, provides $3,042.99 for the delivery of XIFAXAN 550 MG TABLET 60S to the Defense Logistics Agency (DLA). The contract is a Delivery Order with a Firm Fixed Price pricing type, has an ultimate completion date of July 19, 2024, and was awarded on July 18, 2024. No set-aside designation was used for this award. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $23,984.60 firm fixed-price delivery order is for XIFAXAN 550 MG TABLET 60S, a pharmaceutical product, with a completion date of November 27, 2024. The contract is not designated as a set-aside. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $5,923.51 firm fixed-price delivery order is for the drug XIFAXAN 550 mg tablets, with a period of performance through January 30, 2025. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for providing a...
  • SPE2DB20D3103
    Indefinite Delivery Contract
  • SPE2DB20D3103-SPE2DB22FP8L5
    Delivery Order

This federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp is a $3,281.72 Firm Fixed Price delivery order for the supply of XIFAXAN 550 MG tablets. The award is not associated with a set-aside program.

AmerisourceBergen, a major pharmaceutical distributor, holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical through November 2026. This IDC serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The company also maintains a separate $750,000 IDC with the Department of Justice Federal Bureau of Investigation through May 2024, covering similar medical products and prescription drugs.

These IDCs enable efficient government procurement of essential pharmaceutical and medical supplies, serving the healthcare needs of military personnel, veterans, and other federal beneficiaries through streamlined contracting mechanisms.

Generated 2/27/25, 10:45 AM